Next-generation regulatory T cell therapy.
Next-generation regulatory T cell therapy.
复制标题
DOI：
10.1038/s41573-019-0041-4
复制
发表时间：
2019-10
期刊：
影响因子：
--
通讯作者：
Tang Q
中科院分区：
文献类型：
--
作者：
Ferreira LMR;Muller YD;Bluestone JA;Tang Q
调节性T细胞(Treg细胞)是一小部分免疫细胞，致力于抑制过度的免疫激活和维持免疫动态平衡。因此，Treg细胞发育或功能的缺陷会导致免疫反应失控和组织破坏，并可能导致移植物抗宿主病、移植排斥和自身免疫性疾病等炎症性疾病。由于Treg细胞部署了十几种分子机制来抑制免疫反应，它们有可能成为治疗炎症性疾病的多方面适应性智能疗法。事实上，Treg细胞疗法的早期临床试验已经显示出在这些疾病环境中的可行性、耐受性和潜在的疗效。与此同时，在过去20年中，嵌合抗原受体的开发和基因组编辑(包括CRISPR-Cas9的应用)的进展促进了癌症初级T细胞治疗的遗传优化。这些技术现在被用来增强Treg细胞的特异性和功能。在这篇综述中，我们描述了在设计和实施基于Treg细胞的治疗在自身免疫和移植方面的关键进展和前景。
Regulatory T cells (Treg cells) are a small subset of immune cells that are dedicated to curbing excessive immune activation and maintaining immune homeostasis. Accordingly, deficiencies in Treg cell development or function result in uncontrolled immune responses and tissue destruction and can lead to inflammatory disorders such as graft-versus-host disease, transplant rejection and autoimmune diseases. As Treg cells deploy more than a dozen molecular mechanisms to suppress immune responses, they have potential as multifaceted adaptable smart therapeutics for treating inflammatory disorders. Indeed, early-phase clinical trials of Treg cell therapy have shown feasibility, tolerability and potential efficacy in these disease settings. In the meantime, progress in the development of chimeric antigen receptors and in genome editing (including the application of CRISPR–Cas9) over the past two decades has facilitated the genetic optimization of primary T cell therapy for cancer. These technologies are now being used to enhance the specificity and functionality of Treg cells. In this Review, we describe the key advances and prospects in designing and implementing Treg cell-based therapy in autoimmunity and transplantation.
登录
查看更多内容
影响因子：
14.8
作者：
Chang ZL;Lorenzini MH;Chen X;Tran U;Bangayan NJ;Chen YY
通讯作者：
Chen YY
影响因子：
24.5
作者：
Canavan JB;Scottà C;Vossenkämper A;Goldberg R;Elder MJ;Shoval I;Marks E;Stolarczyk E;Lo JW;Powell N;Fazekasova H;Irving PM;Sanderson JD;Howard JK;Yagel S;Afzali B;MacDonald TT;Hernandez-Fuentes MP;Shpigel NY;Lombardi G;Lord GM
通讯作者：
Lord GM
影响因子：
14.8
作者：
Bak RO;Dever DP;Porteus MH
通讯作者：
Porteus MH
影响因子：
56.9
作者：
Anderson, MS;Venanzi, ES;Mathis, D
通讯作者：
Mathis, D
DOI：
10.1084/jem.143.6.1391
发表时间：
1976-06-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Cantor H;Shen FW;Boyse EA
通讯作者：
Boyse EA